Cannabis Pharmaceuticals Market Size & Share, by Brand Type (Sativex, Epidiolex) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2025-2037

Europe Market Analysis

Europe cannabis pharmaceuticals market is likely to dominate revenue share of around 56.3% by the end of 2037. The region’s progress is led by its pharmaceutical excellence and the strong presence of giant medicine producers. As the oriented policies evolved in developed countries such as Germany, France, and Switzerland, the use of marijuana in medicinal applications increased. Thus, the established frameworks of these nations are fostering a lucrative landscape for this category. For instance, in March 2021, STADAPHARM GmbH unveiled a new form of its existing pain therapy pipeline by adding medical cannabis as a primary indication for the treatment of chronic pain patients. This is a suitable alternative to established opioids that have a multidisciplinary use in neurology and oncology.

Germany is augmenting the cannabis pharmaceuticals market with extensive prescription utility and R&D activities. The country is solidifying its position in the current international scenario by introducing innovative extraction technologies and well-diversified distribution channels. According to the OEC data, Germany became the top importer of hemp fibers including cannabis sativa in the world with a value of USD 12.0 million in 2023. This signifies a notable consumption of these legalized compounds, which are mostly used in developing medicines, making this country a center of attraction for leaders. For instance, in February 2025, Tilray Medical consolidated its leadership in Germany by extending its commodities with new cannabis extract products and formulations.

The UK market is propagating with clinical advancements and extensive R&D efforts. The country’s efforts to attain a sufficient supply of high-quality extracts for the domestic consumer base are leveraging its progress in this field. On this note, in November 2023, the team of IPS Pharma and Grow Group opted for AVD (Advanced Vapor Devices) to supply hardware for the commercial launch of the UK-formulated medical cannabis extracts brand, Vida Vapes. In addition, its strong emphasis on API production and discovery is fueling this sector’s growth, creating a new scope of business. For instance, in March 2024, Brains Bio launched a new cannabis-based active pharmaceutical ingredient (API), solid tetrahydrocannabinol (THC). 

APAC Market Statistics

Asia Pacific is predicted to register one of the fastest growth rates in the cannabis pharmaceuticals market by the end of 2037. The region is filled with biodiversity and bioavailability, which ensures an uninterrupted supply of raw materials for therapeutic production. In addition, the pharmaceutical manufacturing powerhouses of this region such as China and India are significantly contributing to this cohort. Moreover, the acceptance from countries with well-established healthcare infrastructure such as Japan and Australia are encouraging others to participate by offering scope for greater revenues. For instance, MediPharm Labs, a precision-based cannabinoids producer, revealed its quarter results of 2024, highlighting a record GMP sales of USD 2.5 million from Australia. 

India, with its ancient roots in plant-based medicine, Ayurveda, is presenting a lucrative opportunity for the market. The rising demand for medicinal plants and extracts in this country to curate nutraceuticals is boosting this sector. According to IBEF data, the medical plant industry is projected to attain USD 188.6 million by 2026 while exhibiting a CAGR of 38.5%. Such a readymade business environment in this country is also propelled by governmental support for extensive R&D, which magnifies the market reach. For instance, in July 2023, a medical research-based initiative, the Cannabis Research Project was commenced under the public-private partnership between CSIR-IIIM Jammu and a Canadian firm.

China is one of the largest suppliers and acquirers of raw materials for the producers in the market. The well-balanced inflow and outflow of resources in this country is fostering a healthy trading atmosphere for this field. According to the 2023 OEC database, China ranked as the 4^th largest importer of hemp fibers (cannabis sativa) in the world with a value of USD 4.7 million. The country is also reported to become the fastest-growing exporter in this category, accounting for USD 1.3 million in the same year. Thus, many domestic and international biopharma pioneers are finding deep interest in cultivating this genre of pharmaceuticals in China.